TY - JOUR T1 - Control of COVID-19 transmission on an urban university campus during a second wave of the pandemic JF - medRxiv DO - 10.1101/2021.02.23.21252319 SP - 2021.02.23.21252319 AU - Davidson H. Hamer AU - Laura White AU - Helen E. Jenkins AU - Christopher J. Gill AU - Hannah N. Landsberg AU - Catherine Klapperich AU - Katia Bulekova AU - Judy Platt AU - Linette Decarie AU - Wayne Gilmore AU - Megan Pilkington AU - Trevor L. McDowell AU - Mark A. Faria AU - Douglas Densmore AU - Lena Landaverde AU - Wenrui Li AU - Tom Rose AU - Stephen P. Burgay AU - Candice Miller AU - Lynn Doucette-Stamm AU - Kelly Lockard AU - Kenneth Elmore AU - Tracy Schroeder AU - Ann M. Zaia AU - Eric D. Kolaczyk AU - Gloria Waters AU - Robert A. Brown Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/26/2021.02.23.21252319.abstract N2 - Importance The COVID-19 pandemic had a wide-ranging impact on educational institutions across the United States. Given potential financial challenges and adverse psychosocial effects of campus closure, as done in the spring of 2020 in response to the first wave, many institutions of higher education developed strategies to allow campuses to reopen and operate in the fall despite the ongoing threat of COVID-19. Many however opted to have limited campus re-opening in order to minimize potential risk of spread of SARS-CoV-2.Objective To analyze how Boston University (BU) fully reopened its campus in the fall of 2020 and controlled COVID-19 transmission despite worsening transmission in the city of Boston.Design Multi-faceted intervention case study.Setting Large urban university campus.Interventions The BU response included a high-throughput SARS-CoV-2 PCR testing facility with capacity to delivery results in less than 24 hours; routine asymptomatic screening for COVID-19; daily health attestations; compliance monitoring and feedback; robust contact tracing, quarantine and isolation in on campus facilities; face mask use; enhanced hand hygiene; social distancing recommendations; de-densification of classrooms and public places; and enhancement of all building air systems.Main Outcomes and Measures Between August and December 2020, BU conducted >500,000 COVID-19 tests and identified 719 individuals with COVID-19: 627 (87.2%) students, 11 (1.5%) faculty, and 212 (25.5%) staff. Overall, about 1.8% of the BU community tested positive. Infections among faculty and staff were mostly acquired off campus, while undergraduate infections were more likely acquired in non-classroom campus settings. Of 837 close contacts traced, 86 (10.3%) tested positive for COVID-19. BU contact tracers identified a source of transmission for 51.5% of cases with 55.7% identifying a source outside of BU. Among infected faculty and staff with a known source of infection, the majority reported a transmission source outside of BU (100% for faculty and 79.8% for staff).Conclusions and Relevance BU was successful in containing COVID-19 transmission on campus while minimizing off campus acquisition of COVID-19 from the greater Boston area. A coordinated strategy of testing, contact tracing, isolation and quarantine, with robust management and oversight, can control COVID-19 transmission, even in an urban university setting.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis was an internally funded project and analysis.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The plan for this analysis was reviewed by the Boston University Charles River Campus Institutional Review Board (IRB) and was classified as non-human subjects research. The BU Medical Center IRB reviewed the safe behavior quality improvement project (Supplement 1.17) and determined it to be exempt.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA limited data set can be made available upon request if accompanied by an acceptable data analysis plan. ER -